QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:VTGN

Vistagen Therapeutics (VTGN) News Today

$5.15
-0.04 (-0.77%)
(As of 09/21/2023 ET)
Compare
Today's Range
$5.08
$5.29
50-Day Range
$1.68
$13.05
52-Week Range
$1.62
$24.71
Volume
144,006 shs
Average Volume
787,723 shs
Market Capitalization
$48.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00
SourceHeadline
MarketBeat logoVistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.0% in August
americanbankingnews.com - September 16 at 3:22 AM
markets.businessinsider.com logoMaxim Group Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)
markets.businessinsider.com - September 13 at 6:13 PM
finance.yahoo.com logoVistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
finance.yahoo.com - September 12 at 9:25 AM
finance.yahoo.com logoVistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
finance.yahoo.com - September 5 at 5:14 PM
finance.yahoo.com logoVistagen Appoints Cindy Anderson as Chief Financial Officer
finance.yahoo.com - August 22 at 6:07 PM
finance.yahoo.com logoVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript
finance.yahoo.com - August 15 at 6:40 PM
markets.businessinsider.com logoMaxim Group Remains a Buy on VistaGen Therapeutics (VTGN)
markets.businessinsider.com - August 12 at 4:04 PM
247wallst.com logoCommodore Capital Buys in for the Long Haul With 20% Vistagen Stake on Promising Phase 3 Data
247wallst.com - August 11 at 8:01 PM
seekingalpha.com logoVistaGen Therapeutics GAAP EPS of -$0.94 misses by $0.08, revenue of $0.17M
seekingalpha.com - August 11 at 2:57 AM
finance.yahoo.com logoSubsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results
finance.yahoo.com - August 11 at 2:57 AM
finance.yahoo.com logoAffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
finance.yahoo.com - August 10 at 10:38 AM
benzinga.com logoWhat's Going On With VistaGen Therapeutics Stock?
benzinga.com - August 8 at 9:16 PM
msn.com logoMaxim Group Upgrades VistaGen Therapeutics (VTGN)
msn.com - August 8 at 9:16 PM
finance.yahoo.com logoVistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
finance.yahoo.com - August 8 at 9:16 PM
marketbeat.com logo
marketbeat.com - August 8 at 9:57 AM
marketwatch.com logoVistaGen Shares Explode After Successful Fasedienol Trial
marketwatch.com - August 8 at 6:14 AM
msn.com logoVistagen's Big Breakthrough: Says Single Administration Of Nasal Spray Candidate Can Potentially Reduce Anxiety Symptoms, Stock Skyrockets
msn.com - August 8 at 6:14 AM
finance.yahoo.com logoBiotech Firm Pops 677% on Social Anxiety Spray Trial Success
finance.yahoo.com - August 8 at 6:14 AM
finance.yahoo.com logoSocial anxiety nasal spray study results make Peninsula biotech's stock shoot up more than 600%
finance.yahoo.com - August 8 at 6:14 AM
investorplace.com logoWhy Is Vistagen Therapeutics (VTGN) Stock Up 650% Today?
investorplace.com - August 7 at 5:12 PM
marketbeat.com logo
marketbeat.com - August 7 at 9:42 AM
marketbeat.com logo
marketbeat.com - August 7 at 9:34 AM
finance.yahoo.com logoVistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
finance.yahoo.com - August 7 at 8:53 AM
marketbeat.com logo
marketbeat.com - August 7 at 8:26 AM
finance.yahoo.com logoVistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
finance.yahoo.com - July 17 at 8:35 AM
finance.yahoo.com logoVistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
finance.yahoo.com - July 13 at 6:55 PM
finance.yahoo.com logoVistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
finance.yahoo.com - June 28 at 8:12 PM
finance.yahoo.com logoVistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
finance.yahoo.com - June 27 at 6:07 PM
finance.yahoo.com logoVistagen Regains Full Compliance with Nasdaq Listing Requirements
finance.yahoo.com - June 23 at 9:20 AM
finance.yahoo.com logoVistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder
finance.yahoo.com - June 21 at 10:25 AM
finance.yahoo.com logoVistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine
finance.yahoo.com - June 13 at 8:06 AM
markets.businessinsider.com logoVistagen's Nasal Spray Shows Efficacy In Menopausal Hot Flashes
markets.businessinsider.com - June 7 at 2:45 PM
finance.yahoo.com logoVistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
finance.yahoo.com - June 7 at 9:44 AM
finance.yahoo.com logoVistagen to Present at Jefferies 2023 Global Healthcare Conference
finance.yahoo.com - June 6 at 6:41 PM
finance.yahoo.com logoVistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
finance.yahoo.com - June 1 at 4:06 PM
finance.yahoo.com logoVistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
finance.yahoo.com - May 30 at 7:43 PM
finance.yahoo.com logoVistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health
finance.yahoo.com - May 24 at 10:26 AM
finance.yahoo.com logoVistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference
finance.yahoo.com - April 19 at 1:36 PM
marketwatch.com logoInvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Portfolio with New European Patent for AV-101
marketwatch.com - April 7 at 9:42 AM
benzinga.com logoWhy VistaGen Therapeutics Stock Is Trading Higher Today
benzinga.com - April 6 at 1:25 PM
finance.yahoo.com logoVistagen Receives New European Patent for AV-101
finance.yahoo.com - April 6 at 1:25 PM
finance.yahoo.com logoSocial Anxiety Disorder Impacts Around 23.7M People In US, Vistagen Releases Details Around Nasal Spray Treatment Program For It
finance.yahoo.com - March 30 at 7:32 PM
finance.yahoo.com logoFDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder
finance.yahoo.com - March 30 at 9:31 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Humacyte (HUMA)
markets.businessinsider.com - March 24 at 5:55 PM
seekingalpha.com logoVistagen up 17% after Phase 3 data for anxiety candidate
seekingalpha.com - March 22 at 1:00 PM
finance.yahoo.com logoVistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
finance.yahoo.com - March 22 at 1:00 PM
markets.businessinsider.com logoMaxim Group Sticks to Its Hold Rating for VistaGen Therapeutics (VTGN)
markets.businessinsider.com - March 9 at 5:46 PM
finance.yahoo.com logoVistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
finance.yahoo.com - March 8 at 9:21 AM
finance.yahoo.com logoVistagen to Present at Cowen 43rd Annual Health Care Conference
finance.yahoo.com - March 2 at 8:40 AM
finance.yahoo.com logoVistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
finance.yahoo.com - March 1 at 12:37 PM
Get Vistagen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.



VTGN Media Mentions By Week

VTGN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VTGN
News Sentiment

0.98

0.49

Average
Medical
News Sentiment

VTGN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VTGN Articles
This Week

1

1

VTGN Articles
Average Week

Get Vistagen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:VTGN) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -